Follow the Caris Life Sciences, Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was reported on 4 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Spetzler David Baxley. All data is accessible without an account.
51
Insider Decl.
n/a
Thresholds
€946,803
3 ops.
Buy Volume
€30m
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Caris Life Sciences, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
45Σ signal
Buys €946,803€30m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,399 of 29,062 companies
16.8
score / 100
Value
24
Quality
10
FCF yld-3.8%
Earn yld-4.8%
EV/EBITDA·
ROE-40%
Gross mgn·
Net mgn-16%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Caris Life Sciences, Inc. es una empresa de medicina de precisión que ofrece soluciones de diagnóstico y pruebas genómicas para ayudar a personalizar los tratamientos de los pacientes. Cotiza en el NASDAQ bajo el ticker XNAS.